ANI (ANIP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended December 2024, ANI Pharmaceuticals (ANIP) reported revenue of $190.57 million, up 44.8% over the same period last year. EPS came in at $1.63, compared to $1.00 in the year-ago quarter.
The reported revenue represents a surprise of +8.98% over the Zacks Consensus Estimate of $174.88 million. With the consensus EPS estimate being $1.44, the EPS surprise was +13.19%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how ANI performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Rare disease pharmaceutical products: $87.04 million versus $86.46 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +108.5% change.
- Net Revenues- Rare disease pharmaceutical products - Cortrophin Gel: $59.40 million versus the four-analyst average estimate of $59.45 million.
- Net Revenues- Rare disease pharmaceutical products - ILUVIEN and YUTIQ: $27.64 million compared to the $27.15 million average estimate based on four analysts.
- Net Revenues- Generic pharmaceutical products: $78.60 million compared to the $76.68 million average estimate based on four analysts.
Shares of ANI have returned -8.4% over the past month versus the Zacks S&P 500 composite's -2.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available